{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:55:16Z","timestamp":1793145316684,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bbrc.2025.151782","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:53:29Z","timestamp":1744174409000},"page":"151782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Intravesical chemotherapy enhances anti-tumor immunity in bladder cancer by modulating CD8+ T cell activation and Treg populations"],"prefix":"10.1016","volume":"764","author":[{"given":"Rui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1130","key":"10.1016\/j.bbrc.2025.151782_bib1","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20211033","article-title":"Understanding breast cancer as a global health concern","volume":"95","author":"Wilkinson","year":"2022","journal-title":"Br. J. Radiol."},{"issue":"19","key":"10.1016\/j.bbrc.2025.151782_bib2","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.bbrc.2025.151782_bib3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/978-3-030-59038-3_17","article-title":"The tumor microenvironment of bladder cancer","volume":"1296","author":"Hatogai","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"9","key":"10.1016\/j.bbrc.2025.151782_bib4","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1111\/cas.14564","article-title":"Report of the use of patient-derived xenograft models in the development of anticancer drugs in Japan","volume":"111","author":"Tsumura","year":"2020","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.bbrc.2025.151782_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/ijms24010123","article-title":"Tumor-microenvironment characterization of the MB49 non-muscle-invasive bladder-cancer orthotopic model towards new therapeutic strategies","volume":"24","author":"Domingos-Pereira","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.151782_bib6","series-title":"Archived from the Original on 21 June 2022","article-title":"European medicines agency (EPAR)","year":"2018"},{"issue":"4","key":"10.1016\/j.bbrc.2025.151782_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4103\/1735-5362.378090","article-title":"Anti-metastatic effect of taraxasterol on prostate cancer cell lines","volume":"18","author":"Movahhed","year":"2023","journal-title":"Res. Pharmaceut. Sci."},{"key":"10.1016\/j.bbrc.2025.151782_bib8","series-title":"Archived from the Original on 21 June 2022","year":"2012"},{"issue":"4","key":"10.1016\/j.bbrc.2025.151782_bib9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4103\/0973-1482.139267","article-title":"An overview of doxorubicin formulations in cancer therapy","volume":"10","author":"Rivankar","year":"2014","journal-title":"J. Cancer Res. Therapeut."},{"issue":"12","key":"10.1016\/j.bbrc.2025.151782_bib10","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1080\/14737140.2021.1991316","article-title":"Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy","volume":"21","author":"Sohail","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"2","key":"10.1016\/j.bbrc.2025.151782_bib11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.bbrc.2025.151782_bib12","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nm863","article-title":"Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity","volume":"9","author":"Curiel","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2025.151782_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.tps8103","article-title":"KEYNOTE-024: phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1)","volume":"33","author":"Brahmer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2025.151782_bib14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejphar.2019.04.001","article-title":"The effect of medicinal plants on multiple drug resistance through autophagy: a review of in vitrostudies","volume":"852","author":"Sameiyan","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.151782_bib15","doi-asserted-by":"crossref","first-page":"16824","DOI":"10.1002\/jcp.28358","article-title":"PD-1\/PD-L1 pathway: basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"10.1016\/j.bbrc.2025.151782_bib16","first-page":"210","article-title":"Biomarkers for response to Anti-PD-1\/Anti-PD-L1 immune checkpoint inhibitors: a large meta-analysis","volume":"37","author":"Mariam","year":"2023","journal-title":"Oncology"},{"key":"10.1016\/j.bbrc.2025.151782_bib17","article-title":"Anti-lung cancer synergy of low-dose doxorubicin and PD-L1 blocker co-delivered via mild photothermia-responsive Black phosphorus","author":"Xu","year":"2024","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.bbrc.2025.151782_bib18","article-title":"CD69 and SBK1 as potential predictors of responses to PD-1\/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bbrc.2025.151782_bib19","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/eji.201646837","article-title":"CD69: from activation marker to metabolic gatekeeper","volume":"47","author":"Cibri\u00e1n","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bbrc.2025.151782_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.552949","article-title":"Functional characterization of a dual enhancer\/promoter regulatory element leading human CD69 expression","volume":"11","author":"Redondo-Ant\u00f3n","year":"2020","journal-title":"Front. Genet."},{"issue":"6","key":"10.1016\/j.bbrc.2025.151782_bib21","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1016\/j.juro.2009.08.018","article-title":"MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus calmette-guerin","volume":"182","author":"Chen","year":"2009","journal-title":"J. Urol."},{"issue":"9","key":"10.1016\/j.bbrc.2025.151782_bib22","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2025.151782_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jconrel.2020.07.043","article-title":"Immune cells as tumor drug delivery vehicles","volume":"327","author":"Combes","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bbrc.2025.151782_bib24","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","article-title":"Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study","volume":"55","author":"Gudj\u00f3nsson","year":"2009","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbrc.2025.151782_bib25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J. Urol."},{"key":"10.1016\/j.bbrc.2025.151782_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ucl.2019.09.014","article-title":"Salvage therapy for non\u2013muscle-invasive bladder cancer: novel intravesical agents","volume":"47","author":"Khaled","year":"2020","journal-title":"Urol. Clin."},{"issue":"6","key":"10.1016\/j.bbrc.2025.151782_bib27","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbrc.2025.151782_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101298","article-title":"CTLA-4 (CD152): a versatile receptor for immune-based therapy","volume":"42","author":"Lingel","year":"2019","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.bbrc.2025.151782_bib29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40425-019-0572-6","article-title":"Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer","volume":"7","author":"Ricciuti","year":"2019","journal-title":"J. Immunother. Cancer."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25004966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25004966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:52:55Z","timestamp":1762095175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25004966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"alternative-id":["S0006291X25004966"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.151782","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravesical chemotherapy enhances anti-tumor immunity in bladder cancer by modulating CD8+ T cell activation and Treg populations","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.151782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151782"}}